An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

A significant percentage of patients with RA and ANCA positivity were also diagnosed with AAV, with GPA being the most common subtype.